Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

ABSTRACT: Research in two fronts has enabled the development of therapies that provide significant benefit to cancer patients. One area stems from a detailed knowledge of mutations that activate or inactivate signaling pathways that drive cancer development. This work triggered the development of targeted therapies that lead to clinical responses in the majority of patients bearing the targeted mutation, although responses are often of limited duration. In the second front are the advances in molecular immunology that unveiled the complexity of the mechanisms regulating cellular immune responses. These developments led to the successful targeting of immune checkpoints to unleash anti-tumor T cell responses, resulting in durable long-lasting responses but only in a fraction of patients. In this Revie

SUBMITTER: Sharma P 

PROVIDER: S-EPMC5905674 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature